Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$67.84
-$0.05(-0.07%)
At close: 4:00 PM EDT
$67.84
-$0.05(-0.07%)
Day’s Range― - ―
52-Week Range$30.82 - $118.84
Previous CloseN/A
Volume220.30K
Average Volume (3M)539.76K
Market Cap
$3.42B
Enterprise Value$2.17K
Total Cash (Recent Filing)$861.61M
Total Debt (Recent Filing)$91.31M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Nov 18, 2026EPS Estimate
-2.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.75
Shares Outstanding44,666,233
10 Day Avg. Volume438,988
30 Day Avg. Volume539,764
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$70.67Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-10.03
Revenue Forecast (FY)$180.27M
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Test-Volume GrowthSustained growth in testing volume and revenue indicates expanding customer adoption and commercial reach. Continued provider additions, digital integrations and sales-force expansion could support broader utilization over the next several quarters.
Differentiated Clinical EvidenceLarge-scale clinical validation and low false-positive performance may strengthen GRAIL’s differentiation with physicians and regulators. Evidence of earlier-stage detection can support long-term adoption if translated into approvals, coverage and clinical use.
Low Leverage And Substantial LiquidityVery low leverage and substantial cash provide financial flexibility to fund clinical, regulatory and commercial programs. The Samsung investment also supports international expansion, reducing near-term dependence on debt financing.
Bears Say
Large Losses And Persistent Cash BurnGRAIL remains far from sustainable profitability despite strong revenue growth. Negative gross profit, very large operating losses and ongoing cash burn could require continued use of reserves or external funding, limiting financial flexibility.
NHS-Galleri Primary Endpoint MissThe missed primary endpoint weakens the evidentiary case for broad clinical utility, even though secondary findings were positive. This could complicate regulatory discussions, payer adoption and physician confidence in population screening.
Regulatory Timing UncertaintyApproval remains dependent on an uncertain FDA process, with potential delays affecting commercialization planning and payer discussions. Any slippage would extend the period of heavy investment before broader access and reimbursement become possible.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $30.82 and its highest was $118.84 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $3.42B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Nov 18, 2026 which is in 84 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on Aug 05, 2026. The company reported -$2.56 earnings per share for the quarter, beating the consensus estimate of -$2.656 by $0.096.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -2.6.
How many shares outstanding does Grail Inc have?
Grail Inc has 44,666,233 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$2.56 in its last earnings report, beating expectations of -$2.656. Following the earnings report the stock price went down -14.532%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.67 (4.17% Upside)
$70.67 (4.17% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 834.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive commercial and clinical momentum: strong year-over-year revenue and volume growth, meaningful gross profit improvement, substantial cash including a $110M Samsung strategic investment, and a robust, differentiated clinical evidence base with low false positive rate and high PPV. Key execution items — a completed PMA submission, anticipated FDA advisory committee and sales force expansion — support the company’s pathway to broader access. Offsetting these positives are continued large operating losses and a widened adjusted EBITDA shortfall, the NHS primary endpoint miss, pricing/ASP pressure from channel mix and competitive noise, and timing uncertainty around the FDA advisory committee and U.K. decision-making. Taken together, the highlights (growth, cash runway, unique clinical validation and commercialization readiness) outweigh the lowlights, though execution and regulatory timing risks remain significant.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$70.67
▲(4.17% Upside)
Technical Analysis
Ownership Overview
11.24% Insiders
12.00% Mutual Funds
41.73% Other Institutional Investors
19.50% Public Companies and
Individual Investors